In a significant resurgence of venture capital activity, the week of November 28 to December 5, 2025, witnessed a remarkable uptick in funding for U.S.-based startups. After a relatively quiet Thanksgiving period, investors returned with vigor, pouring substantial amounts into various sectors, including predictions markets, defense technology, artificial intelligence (AI) infrastructure, and biotechnology. This renewed enthusiasm reflects a broader trend of confidence among venture capitalists as they seek to capitalize on innovative solutions and emerging technologies.
Leading the charge was Kalshi, a New York-based predictions market platform that confirmed its much-anticipated Series E funding round of $1 billion. This financing, led by Paradigm, marks one of the largest fintech raises of the year and underscores the growing interest in platforms that facilitate prediction markets. Kalshi’s unique approach allows users to trade on the outcomes of future events, providing a novel way to hedge risks and speculate on various scenarios. The influx of capital will enable Kalshi to expand its offerings and enhance its technological infrastructure, positioning it as a key player in the evolving landscape of financial markets.
Following closely behind was Castelion, a Torrance, California-based startup specializing in hypersonic munitions. Castelion raised an impressive $350 million in Series B financing, led by Altimeter Capital and Lightspeed Venture Partners. The company, founded by a former SpaceX engineer in 2022, is at the forefront of developing advanced defense technologies that promise to revolutionize military capabilities. The funding will be instrumental in accelerating Castelion’s research and development efforts, allowing it to bring cutting-edge solutions to market more rapidly.
In the realm of cloud computing, Eon, a provider of cloud data backup technology tailored for enterprise AI applications, secured $300 million in a Series D funding round. Led by Elad Gil of Gil Capital, this investment elevates Eon’s total funding to $500 million since its inception less than two years ago and boosts its valuation to $4 billion. Eon’s innovative platform addresses the critical need for reliable data backup solutions in an era where data-driven decision-making is paramount. The funding will enable Eon to enhance its product offerings and expand its market reach, catering to the growing demand for robust cloud solutions.
The health insurance sector also saw significant activity, with Curative, an Austin-based startup offering a free out-of-pocket health plan, raising $150 million in Series B funding. Led by Upside Vision Fund, this financing values Curative at $1.27 billion and highlights the increasing interest in alternative healthcare models that prioritize affordability and accessibility. Curative’s innovative approach aims to disrupt traditional health insurance paradigms, making healthcare more accessible to a broader population.
Another notable player in the health insurance space is Angle Health, a San Francisco-based AI platform focused on healthcare benefits. Angle Health closed a Series B funding round of $134 million, which included a combination of debt and equity. Led by Portage Ventures, this investment brings Angle Health’s total funding to nearly $200 million. The company’s AI-driven solutions are designed to streamline healthcare benefits management, making it easier for employers and employees to navigate the complexities of health insurance.
Cybersecurity remains a critical concern for businesses across industries, and 7AI, a Boston-based startup, is addressing this challenge head-on. The company, which specializes in developing tools for scaling AI agents to perform security tasks, raised $130 million in a Series A funding round just ten months after launching from stealth mode. This rapid growth trajectory underscores the urgent need for innovative cybersecurity solutions in an increasingly digital world. The funding will allow 7AI to further develop its technology and expand its customer base.
Tied with 7AI in terms of funding is Protego Biopharma, a San Diego-based biotech firm focused on therapeutics aimed at reprogramming protein folding to address various diseases and disorders. Protego Biopharma raised $130 million in Series B funding, led by Novartis Venture Fund and Forbion. This investment reflects the growing recognition of the importance of protein folding in drug development and disease treatment. The funding will support Protego’s research initiatives and accelerate the development of its therapeutic candidates.
In the biotech sector, Triana Biomedicines, based in Lexington, Massachusetts, secured $120 million in Series B financing for its molecular glue discovery platform. Co-led by Ascenta Capital and Bessemer Venture Partners, this funding will enable Triana to advance its innovative approach to drug discovery, which leverages molecular glues to enhance the efficacy of therapeutic agents. The investment highlights the increasing interest in novel drug development methodologies that have the potential to transform patient outcomes.
Antithesis, a Virginia-based startup specializing in simulation testing tools for software systems, raised $105 million in Series A funding. Led by Jane Street Capital, this investment underscores the growing demand for robust testing solutions in an era where software reliability is paramount. Antithesis’s innovative tools aim to streamline the testing process, enabling developers to identify and address issues more efficiently.
Finally, Axiado, a San Jose-based company focused on developing AI server chips, closed a Series C+ funding round of $100 million, led by Maverick Silicon. Axiado’s chips are designed to optimize space and power consumption in AI servers, addressing a critical need in the rapidly expanding field of artificial intelligence. The funding will support Axiado’s continued innovation and product development, positioning it as a key player in the AI hardware market.
The collective momentum generated by these funding rounds signals a renewed confidence among investors in the U.S. startup ecosystem. As venture capitalists increasingly seek opportunities in sectors poised for growth, the emphasis on innovation and technological advancement remains paramount. From predictions markets to defense technology, AI infrastructure, and biotechnology, the diversity of funded projects reflects a broad spectrum of interests and a commitment to fostering groundbreaking solutions.
As we approach the end of 2025, the landscape of venture capital is evolving, with investors demonstrating a willingness to back ambitious startups that are tackling some of the most pressing challenges facing society today. The substantial funding secured by these companies not only provides them with the resources needed to scale their operations but also serves as a testament to the transformative potential of technology in shaping the future.
In conclusion, the recent surge in funding rounds highlights the resilience and dynamism of the U.S. startup ecosystem. As investors continue to write large checks, the stage is set for a new wave of innovation that promises to redefine industries and improve lives. The coming months will be crucial for these startups as they leverage their newfound capital to drive growth, enhance their offerings, and ultimately make a lasting impact in their respective fields. With the right support and strategic vision, these companies are well-positioned to lead the charge into a future characterized by technological advancement and societal progress.